Ratings Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
68 ^USD	-4.97%		-8.34%	-18.55%

Apr. 09	Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	MT
Apr. 05	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CYTOKINETICS, INCORPORATED	-18.55%	7.12B	B
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+2.31%	96.56B	B+
ARGENX SE	+1.46%	22.61B	B
BIONTECH SE	-16.72%	21.18B	B+
GENMAB A/S	-4.36%	19.07B	A-
WUXI APPTEC CO., LTD.	-41.75%	16.53B	A-
BEIGENE, LTD.	-23.26%	14.46B	B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.25B	C+
SAREPTA THERAPEUTICS, INC.	+22.69%	11.1B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes